Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-09-21

CRISPR Therapeutics AG

CRISPR Therapeutics develops gene-edited medicines, shares CASGEVY economics with Vertex, and is advancing wholly owned in vivo and cell-therapy programs.

ai biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof exists, but value capture is still gated

The company has crossed the hardest credibility threshold by helping bring the first CRISPR-based therapy to market. The next rerating needs one owned asset to look commercially real, not just scientifically promising.

Analysis

Thesis

CRISPR Therapeutics can rerate from a cash-backed proof story into a multi-franchise genetic medicines company by 2031 if CASGEVY keeps widening access and at least one wholly owned follow-on asset becomes launch-visible, because that would shift value capture from partner-mediated validation toward direct product economics.

Last Economy Alignment

AI should make target discovery and design cheaper, which helps a reusable gene-editing platform, but CRSP still wins or loses on clinical proof, regulatory trust and manufacturing rather than software-style scale.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.4x (from 5 most recent analyses)

Reasoning

The upside case is a step-up from single-product proof to platform credibility with one internally controlled launch path. CASGEVY can keep building trust and cash generation, while a clean follow-on asset would let investors pay for repeatability rather than only for optionality. I do not underwrite software-like compounding because access, manufacturing and regulation remain hard bottlenecks.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is slow proof conversion rather than near-term survival. CRISPR must turn first approval into repeatable approvals, reduce dependence on Vertex for visible value capture, and show that owned programs can be safe, durable, manufacturable and commercially legible before the market will award a sustained premium platform valuation.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No new thesis-changing 8-K, clinical readout or regulatory event was disclosed in the last 7-10 days; the core thesis still rests on the August 28, 2026 CTX310 update and the August 3, 2026 Q2 business update.
A September 17, 2026 routine insider Form 144 appeared, but I do not view it as fundamental evidence against the operating thesis.
The share price moved higher into September 21, 2026 without a matching new de-risking event, which slightly compresses forward upside from the current starting point.

Forecast update

The opportunity set is similar, but the starting valuation is a bit richer than in the prior snapshot, so upside is modestly less asymmetric absent a fresh proof event.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.32

They control gene-editing know-how, clinical learning and some manufacturing, so cheaper AI-driven discovery gives them more shots on goal. But biology, regulation and treatment-center bottlenecks still decide the outcome, so this is only a moderate AI-era winner unless more programs become real medicines.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$87.56

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research